42822-57-1

Usage

Uses

Used in Organic Chemistry:
DIETHYL(4-AMINOPHENYL)PHOSPHONATE is used as a synthetic intermediate for introducing the phosphonate group into organic molecules, facilitating the creation of a wide range of organic phosphorous compounds.
Used as a Flame Retardant Additive:
In the Polymer and Plastics Industry, DIETHYL(4-AMINOPHENYL)PHOSPHONATE is used as a flame retardant additive to enhance the fire resistance of polymers and plastics, thereby improving their safety characteristics.
Used in Pharmaceutical Development:
Due to its unique chemical properties, DIETHYL(4-AMINOPHENYL)PHOSPHONATE is studied for potential uses in pharmaceuticals, where it may contribute to the development of new drugs or drug delivery systems.
Used in Agrochemicals:
DIETHYL(4-AMINOPHENYL)PHOSPHONATE is also being explored for its potential applications in agrochemicals, where it could be utilized in the development of new pesticides or other agricultural chemicals to improve crop protection and yield.

InChI:InChI=1/C10H16NO3P/c1-3-13-15(12,14-4-2)10-7-5-9(11)6-8-10/h5-8H,3-4,11H2,1-2H3

Upstream product

• 762-04-9 phosphonic acid diethyl ester 
• 540-37-4 p-aminoiodobenzene 
• 29800-93-9 diethyl phosphite 
• 367-24-8 4-bromo-2-fluoroaniline 
• 106-40-1 4-bromo-aniline 
• 615-57-6 2,4-dibromo-aniline 
• 89620-99-5 silver diethyl phosphonate 
• 1246999-26-7 diethyl 4-(4-hydroxy-phenylazo)phenylphosphonate 
• 636-98-6 p-nitrobenzene iodide 
• 122-52-1 triethyl phosphite 
• 586-78-7 para-nitrophenyl bromide 
• 62956-32-5 4-acetylaminophenylphosphonic acid diethyl ester 
• 1754-42-3 para-nitro-phenylphosphonate diethylique 
• 20677-12-7 diethyl (4-bromophenyl)phosphonate 

Downstream Products

• 5337-17-7 4-aminophenylphosphonic acid 
• 345352-13-8 (4-isocyanato-phenyl)-phosphonic acid diethyl ester 
• 1158383-73-3 diethyl 4-(n-octylsulfonamido)phenylphosphonate 
• 1234367-42-0 (E)-3-(4-(4-(N-(4-(diethoxyphosphoryl)phenyl)sulfamoyl)phenoxy)-3,5-difluorophenyl)-2-methylacrylic acid 
• 1422568-49-7 (E)-tert-butyl methyl(4-(4-(prop-2-yn-1-yloxy)styryl)phenyl)carbamate 
• 1422568-50-0 (E)-tert-butyl (4-(4-((1-(3-aminopropyl)-1H-1,2,3-triazol-4-yl)methoxy)styryl)phenyl)methylcarbamate 
• 1422568-51-1 (E)-tri-tert-butyl 2,2′,2″-(10-(2-((3-(4-((4-(4-((tert-butoxycarbonyl)(methyl)amino)styryl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 1456602-23-5 diethyl 4-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)phenylphosphonate 
• 1456602-18-8 diethyl 4-(4-phenoxybenzamido)phenylphosphonate 
• 1606169-24-7 diethyl (4-{[6-(3-aminophenyl)pyrimidin-4-yl]amino}phenyl)phosphonate 
• 1606169-27-0 (4-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonic acid 
• 1606169-28-1 (4-{[6-(3-aminophenyl)pyrimidin-4-yl]amino}phenyl)phosphonic acid 
• 1606169-22-5 diethyl (4-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonate 
• 1606169-23-6 diethyl (4-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphonate 

Relevant academic research and scientific papers

STRAD-BINDING AGENTS AND USES THEREOF

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

STAT3 DIMERIZATION INHIBITORS

The subject matter disclosed herein relates to compositions and methods of making and using the compositions. In a further aspect, the subject matter disclosed herein relates to inhibitors of STAT3 dimerization. Methods of making these compositions as wel

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors

Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

First reusable ligand-free palladium catalyzed C-P bond formation of aryl halides with trialkylphosphites in neat water

A reusable ligand-free palladium catalyzed phosphonation of aryl iodides, bromides and chlorides with trialkylphosphites is described for the first time in neat water. The aryl phosphonates are obtained in good to excellent yields. The reaction can be also performed with Ni(II) with longer reaction time. The role of tetrabutylammonium bromide in this reaction as reducing agent for generation of Pd(0) at room temperature is also demonstrated. Pd(0)/TBAB was easily reused for three runs without decreasing the efficiency.

Development of new N-arylbenzamides as STAT3 dimerization inhibitors

The O-tosylsalicylamide S3I-201 (10) was used as a starting point for design and synthesis of novel STAT-3 dimerization inhibitors with improved drug-like qualities. The phosphonic acid 12d and salicylic acids 13f, 13g with a shorter amide linker lacking

An improved procedure for the synthesis of aryl phosphonates by palladium-catalysed cross-coupling of aryl halides and diethyl phosphite in polyethylene glycol

A general and greener protocol for the synthesis of aryl phosphonates by the cross-coupling of aryl halides and diethyl phosphite using tetrakis(triphenylphosphine)palladiume/triethylamine/polyethylene glycol 600 [Pd(PPh3)4/ Et3N/PEG 600] as an efficient catalytic system has been developed. This procedure also avoids hazardous solvents and is therefore an eco-friendly alternative to the existing methods.

Optimization of the azobenzene scaffold for reductive cleavage by dithionite; development of an azobenzene cleavable linker for proteomic applications

In this paper we conducted an extensive reactivity study to determine the key structural features that favour the dithionite-triggered reductive cleavage of the azo-arene group. Our stepwise investigation allowed identification of a highly reactive azo-arene structure 25 bearing a carboxylic acid, at the ortho position of the electron-poor arene and an ortho-Oalkyl-resorcinol as the electron-rich arene. Based on this 2(2′-alkoxy-4′-hydroxyphenylazo) benzoic acid (HAZA) scaffold, the orthogonally protected difunctional azo-arene cleavable linker 26 was designed and synthesized. Selective linker deprotection and derivatization was performed by introducing an alkyne reactive group and a biotin affinity tag. This optimized azo-arene cleavable linker led to a total cleavage in less than 10 s with only 1 mM dithionite. Similar results were obtained in biological media.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract

Direct synthesis of amino-substituted aromatic phosphonates via palladium-catalyzed coupling of aromatic mono-and dibromides with diethyl phosphite

An efficient Pd-catalyzed carbon-phosphorus bond-forming route is described for the direct synthesis of diethyl arylphosphonates bearing amino and alkylamino groups on the aromatic ring. Copyright

Development of a room temperature Hirao reaction

Arylphosphonates were prepared at 25 °C through the palladium-catalyzed coupling of aryl iodides with a silver phosphonate. A wide range of aryl iodides were successfully employed including phenolic substrates as well as those containing an ortho substitu